2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 163

Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Abstract Number: 164

Association of Natural Killer Cell Ligand Polymorphism, HLA-C Asn80Lys, with the Development of Anti-SSA/Ro Associated Congenital Heart Block
Abstract Number: 165

Rheumatoid Arthritis Risk Polymorphisms in CCR6, SNP and Estrogen-Dependent Response to Immune Mediator Gene Expression, and NF-κb Transcriptional Activity: Crosstalk between the Immune and Endocrine Systems
Abstract Number: 166

Integrative Systems Biology Approach Identifies Key Transcription Factors and Novel Rheumatoid Arthritis (RA) and Individualized Therapeutic Targets
Abstract Number: 167

Differentially Co-Expressed Gene Networks in Previously DMARD-Naïve Patients with Early RA Achieving Sustained Drug-Free Remission after Step-up Methotrexate Therapy
Abstract Number: 168

Identification of Novel Susceptibility Loci in a Large UK Cohort of Juvenile Idiopathic Arthritis (JIA) Cases
Abstract Number: 169

New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant
Abstract Number: 170

Genome-Wide Association Study of Clinically-Ascertained Gout and Subtypes Identifies Multiple Susceptibility Loci Including Transporter Genes
Abstract Number: 171

Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells
Abstract Number: 172

Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis
Abstract Number: 173

Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Abstract Number: 174

Transcriptional Profiling of Synovial Macrophages from RA Patients to Capture Disease Heterogeneity
Abstract Number: 175

Precisely Controlled Differential Gene Expression System to Investigate the Effect of eQTL
Abstract Number: 176

SEC16A and Antigen Presentation Abnormalities in the Pathogenesis of Axial Spondyloarthritis
Abstract Number: 177

Intronic Variants of the B-Cell Proliferator RASGRP3 Affect Its Expression, and Might Contribute to Lupus Risk

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].